Skip Navigation

Skip Navigation

Issue No. 24  | June 06, 2008
View HTML version

AIDSinfo.nih.gov is pleased to provide you with a weekly update of highlights about what has happened in the world of HIV/AIDS treatment, prevention, and research. We hope you find this encapsulated view of HIV/AIDS news useful.

Globe of the earth

infoSIDA Launches Redesigned Home Page!

infoSIDA is proud to announce a new and improved home page design. infoSIDA is the Spanish-language sister site of AIDSinfo and offers information about HIV treatment and clinical trials. All content is available in Spanish and created specifically for patients. The site offers patient-level fact sheets, clinical trial information, a glossary of HIV-related terms, and much more. Additionally, Spanish-speaking health information specialists are available to answer questions by phone at 1-800-448-0440 (M-F, 12-5 pm), online via Live Help (M-F, 12-4 pm), or by e-mail (ContactUs@aidsinfo.nih.gov). 

infoSIDA al instante, the Spanish-language infoSIDA e-newsletter, is now available for easy access from the infoSIDA home page. In addition, a new features section has been added with quick links to popular infoSIDA tools and resources.

More information from infoSIDA is available:


Virologically Suppressed Patients Have Fewer HIV Treatment Regimen Changes Due to Side Effects

In a recent study, researchers found that the rate of HIV regimen change due to side effects is relatively low in virologically suppressed patients--approximately 39% of 508 study participants--and that certain regimens are associated with even fewer treatment changes.

Specifically, treatment regimen combinations that were less likely to be changed due to toxicity included atazanavir, efavirenz, or tenofovir, while there was an increased risk of change due to toxicity in regimens containing lopinavir/ritonavir or stavudine. Several demographic factors were also found to be associated with regimen change. Study results indicate that certain regimens have the potential for long-term use if treatment toxicities are minimized.

More information is available:


ClinicalTrials.gov Info

Subscribe Info

Contact AIDSinfo
Download Adobe Acrobat(R) Reader TM to view PDF files located on this site.
ISSN 1558-3228





previewPage